证券代码：835670 证券简称：数字人 公告编号：2024-013 山东数字人科技股份有限公司 第三届监事会第十六次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2024 年 4 月 16 日 2.会议召开地点：公司会议室 3.会议召开方式：现场 4.发出监事会会议通知的时间和方式：2024 年 3 月 29 日 以电话、即时通讯方式 发出 5.会议主持人：李嘉舜 6.召开情况合法、合规、合章程性说明： 本次会议的召集、召开符合《公司法》、《公司章程》等有关规定。 （二）会议出席情况 会议应出席监事 3 人，出席和授权出席监事 3 人。 二、议案审议情况 （一）审议通过《关于公司 2023 年年度报告及其摘要》议案 1.议案内容： 具体内容详见公司于 2024 年 4 月 17 日 在 北 京 证 券 交 易 所 官 网 （http://www.bse.cn）上披露的《2023 年年度报告》（公告编号：2024-014） 及 ...

山东数字人科技股份有限公司 根据《上市公司独立董事管理办法》、《北京证券交易所股票上市规则（试 行）》及《北京证券交易所上市公司持续监管指引第 1 号—独立董事》等有关 规定，审计委员会成员应当为不在上市公司担任高级管理人员的董事，公司于 2023 年 10 月 25 日召开第三届董事会第十四次会议，同意对公司第三届董事会 审计委员会部分委员进行调整，董事会审计委员会由李增春先生、李承润先生、 徐以发先生三名成员组成，其中独立董事占审计委员会成员总数的 2/3，主任 委员由具备会计资格的独立董事李增春先生担任。审计委员会成员符合监管要 求及《公司章程》等相关文件的规定。 证券代码：835670 证券简称：数字人 公告编号：2024-026 董事会审计委员会 2023 年度履职情况报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 山东数字人科技股份有限公司（以下简称"公司"）第三届董事会审计委员 会根据《公司法》《证券法》《上市公司独立董事管理办法》《北京证券交易所股 票上市规则（试行）》及《北京证券 ...

证券代码：835670 证券简称：数字人 公告编号：2024-025 山东数字人科技股份有限公司 董事会关于独立董事独立性情况的专项报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 根据中国证券监督管理委员会《上市公司独立董事管理办法》等相关规 定，山东数字人科技股份有限公司（以下简称"公司"）董事会就公司在任独 立董事李增春、李承润、王莉的独立性情况进行评估并出具了专项意见。 （四）独立董事及其配偶、父母、子女未在公司控股股东、实际控制人的 附属企业任职； （五）独立董事不是公司及公司控股股东、实际控制人或者其各自的附属 企业有重大业务往来的人员，未在有重大业务往来的单位及其控股股东、实际 控制人任职； （六）独立董事不是为公司及公司控股股东、实际控制人或者其各自附属 企业提供财务、法律、咨询、保荐等服务的人员，包括但不限于提供服务的中 介机构的项目组全体人员、各级复核人员、在报告上签字的人员、合伙人、董 事、高级管理人员及主要负责人； 根据独立董事向董事会提供的关于独立性情况的自查报告，结合其他 ...

Financial Investments and Yields - The company purchased low-risk short-term financial products with its own funds, including a 3 million RMB product with an annual yield of 2.685%-3.395%[3], a 2 million RMB product with an annual yield of 6.277%[3], and a 5 million RMB product with an annual yield of 2.41%-2.43%[3] Government Subsidies - The company received government subsidies totaling 7,745,053.89 RMB, including 6,433,052.27 RMB from VAT refunds and 470,000 RMB from the 2023 Technology Innovation Guidance Plan[4] - Government subsidies received totaled 7,744,876.50, compared to 4,718,381.07 in the previous year[21] - Government subsidies are recognized when the conditions attached are met and the subsidies are receivable. Monetary subsidies are measured at the actual amount received, while non-monetary subsidies are measured at fair value or nominal amount (1 yuan) if fair value cannot be reliably determined[80] - The company and its subsidiaries classify government subsidies as either asset-related or income-related. Asset-related subsidies are deferred and recognized over the useful life of the related asset, while income-related subsidies are recognized as income when received[80] Asset and Financial Position - The company's total assets increased to 276,828,764.33 RMB from 272,061,845.68 RMB, with current assets rising to 203,997,015.45 RMB from 195,819,839.52 RMB[6] - The company's cash and cash equivalents increased by 23,498,324.32 RMB, reaching 141,342,846.25 RMB at the end of the year[7] - The company's statutory surplus reserve increased by 1,565,168.97 RMB to 17,190,862.67 RMB[13] - The company's undistributed profit at the end of the year was 74,512,389.43 RMB, up from 64,439,262.25 RMB at the beginning of the year[14] - The company's cash balance at the end of the year was 141,342,846.25, compared to 117,844,521.93 at the beginning of the year[74] - The company's total asset impairment loss was -341,086.66, compared to -394,756.53 in the previous year[67] - The company's long-term equity investment in subsidiaries remained unchanged at 17,000,000.00[76] - The company's total number of employees increased from 232 to 244, with notable increases in doctoral (2 to 3) and master's degree holders (11 to 12)[157] - The company's total share capital at the end of the year is 106,182,400.00 shares[132] - The company's total employee benefits for the year amount to RMB 38,404,721.48[130] - The company's total assets were RMB 276.83 million, with a slight increase of 0.03% compared to the performance forecast[180] - Shareholders' equity attributable to the parent company was RMB 251.94 million, a decrease of 0.10% compared to the performance forecast[180] Profit and Loss - The company's net profit attributable to the parent company's owners was 11,638,296.15 RMB, compared to a loss of 4,244,228.99 RMB in the previous year[14] - The company's consolidated profit for the year amounted to 11,467,535.90, with an income tax expense calculated at the statutory/applicable tax rate of 1,720,130.39[58] - The impact of different tax rates applied by subsidiaries resulted in a reduction of 379,259.19 in income tax expense[58] - The use of previously unrecognized deferred tax assets for deductible losses had a negative impact of 2,086,427.02 on income tax expense[58] - The impact of unrecognized deferred tax assets for deductible temporary differences or losses was 2,791,725.62[58] - Net profit attributable to shareholders was RMB 11.64 million, a decrease of 2.22% compared to the performance forecast[180] - Net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 7.85 million, a decrease of 3.25% compared to the performance forecast[180] - Basic earnings per share were RMB 0.11, with no variance compared to the performance forecast[180] - Weighted average return on equity (pre-deduction) was 4.73%, a decrease of 2.87% compared to the performance forecast[180] - Weighted average return on equity (post-deduction) was 3.19%, a decrease of 3.92% compared to the performance forecast[180] Revenue and Income - Rental income from buildings amounted to 695,502.02[19] - Revenue for the year was RMB 96.58 million, with no variance compared to the performance forecast[180] Accounts Receivable and Bad Debt Provisions - Accounts receivable within 1 year amounted to 27,693,823.71, an increase from 24,851,515.50 in the previous year[41] - Accounts receivable aged 1-2 years decreased significantly to 6,603,330.50 from 25,143,144.29 in the previous year[41] - The company's top five accounts receivable and contract assets at year-end include Wuhan Jinmao Engineering Technology Co., Ltd. with a balance of 9,482,407.20 CNY, accounting for 18.89% of the total[50] - The company's accounts receivable are classified into categories based on the method of bad debt provision. As of the end of the reporting period, the total accounts receivable were 48,925,152.15 yuan, with a bad debt provision of 16,787,354.12 yuan, representing a provision ratio of 34.31%[96] - The company's bad debt provision for significant individual accounts receivable increased from 4,607,672.40 yuan at the beginning of the year to 5,214,627.20 yuan at the end of the year, with a provision ratio of 100%[96][98] - The company recovered or reversed bad debt provisions totaling 4,607,672.40 yuan during the year, primarily due to sales returns from Chongqing Taimin Pharmaceutical Co., Ltd., a subsidiary of Sinopharm Holding[98] - Accounts receivable and contract assets year-end balance totaled 29,944,083.42, with a bad debt provision of 8,945,558.25, accounting for 59.56% of the total[99] - The year-end balance of contract assets was 1,343,874.86, with a bad debt provision of 121,209.39, resulting in a net book value of 1,222,665.47[99] - Other receivables year-end balance was 766,933.08, with a bad debt provision of 176,716.50, representing a provision ratio of 23.04%[102] - The year-end balance of other receivables classified by aging showed 487,826.16 within 1 year, 121,100.00 for 1-2 years, and 158,006.92 for over 3 years[105] - Bad debt provision for accounts receivable is RMB 16,787,354.12, with a book value of RMB 32,137,798.03[126] - Accounts receivable at the end of the reporting period amounted to 32.14 million yuan, accounting for 11.61% of total assets, with 43.27% of receivables aged over 1 year[146] - The company has implemented strict bad debt provision policies for long-aged receivables to accurately reflect asset conditions[146] Leases and Rental Expenses - Short-term lease expenses for the current period were 923,035.72, up from 818,007.32 in the previous year[39] - Interest expenses on lease liabilities for the current period were 112,475.87, down from 177,512.55 in the previous year[39] - Total cash outflows related to leases were 2,772,761.25, slightly lower than the previous year's 2,822,199.34[39] - For leases, the company and its subsidiaries recognize a right-of-use asset and lease liability at the commencement date, except for short-term leases and leases of low-value assets[82] - The company and its subsidiaries measure lease liabilities at the present value of lease payments not yet paid at the commencement date, using the lease's implicit interest rate or the incremental borrowing rate if the implicit rate cannot be determined[91] - The company and its subsidiaries re-measure lease liabilities when there are changes in fixed payments, residual value guarantees, indices or rates used to determine lease payments, or the assessment of purchase, renewal, or termination options[92] - Prepaid rent at the end of the year is RMB 124,076.27, compared to RMB 151,930.17 at the beginning of the year[129] Investments and Equity - The company holds significant influence over its associates, typically when it owns between 20% and 50% of the voting rights, unless there is clear evidence that it cannot participate in the decision-making process[44] - The company uses the equity method to account for investments in joint ventures and associates, adjusting the carrying amount of the investment if the initial cost differs from the share of the net assets' fair value[45] - When the company loses control over a subsidiary, it reclassifies the remaining equity using the equity method if it retains significant influence or joint control, otherwise, it applies the financial instruments accounting standard[46] - The year-end balance of other equity instrument investments remained unchanged at 5,000,000.00, with no additional investments or reductions during the year[110] Fixed Assets and Depreciation - The company's fixed assets, including buildings and equipment, are depreciated using the straight-line method with a residual value rate of 5% and an annual depreciation rate of 4.75% for buildings[51][52] - The year-end book value of fixed assets, including production equipment and office equipment, totaled 44,911,364.08, a slight increase from the previous year's 44,760,875.04[113] Cash Flow and Operating Activities - The company's net cash flow from operating activities was 32,050,406.98, a significant increase from the previous year's 6,984,399.12[74] - The company's cash and cash equivalents increased by 23,498,324.32 RMB, reaching 141,342,846.25 RMB at the end of the year[7] - The company defines cash and cash equivalents as cash on hand and deposits that are readily available for payment, as well as short-term investments with a maturity of no more than three months[56] Tax and Incentives - The company was re-certified as a high-tech enterprise in 2023, enjoying a reduced corporate income tax rate of 15% from 2023 to 2025[146] - The company's subsidiaries, Yichuang Medical and Shenzhen Yichuang, enjoy tax incentives for small and micro enterprises, including a 50% reduction in resource tax, urban maintenance and construction tax, property tax, urban land use tax, stamp tax, farmland occupation tax, education surcharge, and local education surcharge[94] - The company and its subsidiaries recognize deferred tax liabilities for all taxable temporary differences except those arising from initial recognition of goodwill or transactions that do not affect accounting profit or taxable income[81] R&D and Innovation - R&D expenditure for the current period is RMB 22,941,404.20, accounting for 23.75% of operating revenue[135] - The company's R&D expenditure decreased from RMB 25,224,420.88 in the previous period to RMB 22,941,404.20 in the current period[135] - The company has 7 R&D projects in 2023, with 6 focused on digital human projects and 1 on a subsidiary project in Shenzhen[164] - The "High-Definition Digital Human R&D and Industrialization Project" has been upgraded and is set to launch in 2024[164] - The "Digital Human Anatomy System" supports a comprehensive teaching platform covering pre-class, in-class, and post-class activities[164] - The "Digital Human Cloud Platform" has been accessed by over 58,000 students and 3,000 teachers[164] - The company's R&D team has accumulated extensive expertise in medical imaging, computer science, and clinical experience[167] - The company has established a comprehensive R&D management system to ensure project execution and quality[167] - The company's R&D expenses in 2023 were 22.94 million yuan, accounting for 23.75% of the operating revenue[164] - The company has a strong R&D team of over 100 members, covering expertise in computer technology and medicine, and possesses advanced digital anatomy technology platforms, including data acquisition, 3D modeling, and virtual reality technologies[197] - The company's "High-Definition Digital Human Virtual Anatomy Table System" and "Digital Human High-Definition Tomography 3D Printing Model" have been recognized as reaching international advanced and leading levels, respectively, by the Chinese Anatomical Society[197] - The company has launched the Digital Human Cloud Platform, addressing challenges in hybrid online and offline teaching, resource shortages, and uneven distribution of teaching resources, supporting new educational models like flipped classrooms[197] - The company has formed R&D teams with prestigious medical institutions such as the Army Medical University and Shandong University, integrating computer information technology with traditional medicine to develop innovative products[197] - The company holds 14 invention patents and 71 copyrights, with R&D investment exceeding 15% of operating revenue in recent years[199] - The company has won the Shandong Provincial Science and Technology Progress Third Prize in 2014 and the National Teaching Achievement Second Prize in 2018[199] Corporate Governance and Shareholding - The company's controlling shareholder and actual controller, Xu Yifa, directly holds 40.85% of the shares and controls a total of 41.71% of the company's shares[149] - The top ten shareholders collectively hold 55.08% of the company's shares, with no related party relationships among them[148] - Xu Yifa has served as the company's chairman since 2015 and continues to hold this position[149] - The company's board of directors approved the conclusion of some fundraising projects and the permanent replenishment of surplus funds on December 26, 2023[152] - The company's third board of supervisors approved the 2023 semi-annual report and summary on August 24, 2023[152] - The company's 2022 annual report, financial report, and profit distribution plan were approved at the 2022 annual shareholders' meeting on May 22, 2023[152] - The company revised several governance-related systems, including the "Articles of Association," "Board of Directors System," and "Supervisory Board System," during the reporting period[155] - The company's core employees' changes had no significant impact, and no specific measures were taken[158] - The company did not implement any equity incentive plans during the reporting period[160] - The company did not engage in any labor outsourcing during the reporting period[161] Market and Product Development - The company's main products include digital medical education products, life science popularization products, and interactive smart all-in-one machines[186] - The company has established a comprehensive R&D management system, including regulations on R&D projects, documentation, product naming, and review processes, ensuring the execution of R&D projects through stages such as initiation, implementation, and acceptance[192] - The company has collaborated with domestic medical universities, including Shandong University and Inner Mongolia Medical University, to develop high-precision digital human products, achieving high-definition human tomography data acquisition and processing, and has begun product development for clinical diagnostic assistance and sports anatomy[192] - The company's products are widely used in over 500 medical institutions and have been piloted in more than 30 countries overseas, with plans to expand further through promotional activities[197] - The company is focusing on strengthening its market presence in the medical education sector, optimizing product quality, and enhancing core competitiveness to effectively respond to market competition[192] - The company is expanding its overseas medical education market in line with the national "Belt and Road" strategy, aiming to capitalize on historical development opportunities[192] - The company has completed the design and implementation of life science museums in multiple medical universities, leveraging its data and technological advantages in digital medicine[199] - The company's interactive smart all-in-one machine, produced by its wholly-owned subsidiary Shenzhen Yichuang, features high-quality touch panels and is used in various scenarios including education, exhibitions, and video conferencing[199] - The company has established 12 provincial offices nationwide, covering over 60% of the market in medical colleges and universities, solidifying its leading position in the digital anatomy field[199] - The company's core team possesses extensive expertise in computer science and medicine, enabling efficient and precise services[199] - The company plans to expand its business scope from medical education to clinical medicine and public health[199] - The company's products and solutions are highly aligned with the high data professionalism requirements of medical universities[199] - The company has a mature sales network and a complete service closed-loop, with high brand recognition and reputation in the market[199] - The company's technological innovation and brand advantages provide a solid foundation for its high-quality development[199] Risk Management - The company faces risks related to intellectual property infringement and has implemented measures such as patent applications and employee confidentiality agreements[146] - Core technical personnel retention is a key risk, with the company implementing competitive compensation and performance evaluation systems to mitigate this[146] - The company is exposed to risks from changes in tax incentives for software and integrated circuit industries[146] - The company has strengthened credit management and collection systems to reduce accounts receivable risks[146] Fundraising and Projects - The company's "Digital Human Cloud Platform Construction Project" was completed and reached the intended usable state on December 21, 2023, with a remaining fund of 3,795,985.23 yuan (including interest and financial income) permanently replenishing working capital[154] - The company extended the construction period of the "High-Definition Digital Human R&D and Industrialization Construction Project" to December 31, 2024, without changing the funding purpose or investment scale[154] Events and Recognition - The company showcased new technologies and products at the 59th China Higher Education Expo in April[168] - The company hosted the first National Medical College Students' Morphology Reading and Human Anatomy Specimen Identification Skills Competition in May[168] - The company's "High-Definition Digital Human Virtual Anatomy System V1.0" was recognized as a 2023 Shandong Famous Brand[174] - The company's "High-Definition Digital

山东数字人科技股份有限公司 2023 年度 审计报告 | 索引 | 页码 | | --- | --- | | 审计报告 | 1 -- 5 | | 公司财务报表 | | | 合并资产负债表 | 1-2 | | 母公司资产负债表 | 3-4 | | 合并利润表 | 5 | | 母公司利润表 | 6 | | 合并现金流量表 | 7 | | 母公司现金流量表 | 8 | | 合并股东权益变动表 | 9-10 | | 母公司股东权益变动表 | 11-12 | | 财务报表附注 | 13-92 | 联系申话: 信永中和会计师事务所 | 北京市东城区朝阳门北大街 8 号富华大厦 A座 9 层 +86 (010) 6554 elephone: +86 (010) 6554 2288 9/F. Block A. Fu Hua Mansio No.8. Chaovangmen Beidaile Donacheng District, Beijin 100027. P.R.China 86 (010) 6554 7190 审计报告 XYZH/2024JNAA2B0097 山东数字人科技股份有限公司 山东数字人科技股份有限公司全体股 ...

证券代码：835670 证券简称：数字人 公告编号：2024-029 山东数字人科技股份有限公司 2023 年年度权益分派预案公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 为积极履行回报股东义务，与全体股东分享公司经营收益，在统筹考虑战略 发展目标及流动资金需求，保证公司健康、稳定、持续发展的前提下，山东数字 人科技股份有限公司（以下简称"公司"）拟实施 2023 年年度权益分派。 一、权益分派预案情况 根据公司 2024 年 4 月 17 日披露的 2023 年年度报告（财务报告已经审计）， 截至 2023 年 12 月 31 日，上市公司合并报表归属于母公司的未分配利润为 74,512,389.43 元，母公司未分配利润为 83,116,774.35 元。 公司本次权益分派预案如下：公司目前总股本为 106,182,400 股，以未分配 利润向全体股东每 10 股派发现金红利 0.60 元（含税）。本次权益分派共预计派 发现金红利 6,370,944.00 元。 公司将以权益分派实施时股权登 ...

山东数字人科技股份有限公司 募集资金年度存放与使用情况鉴证报告 索引 页码 鉴证报告 关于募集资金 2023 年度存放与使用情况的专项报告 1-9 . ■ 务所 2023 年度 北京市东城区朝阳门北大街 l 联系由话 8号官华大厦A型 Chaovanomen B hena District Re 募集资金年度存放与使用情况鉴证报告 XYZH/2024 INAA2B0099 山东数字人科技股份有限公司全体股东: 我们对后附的山东数字人科技股份有限公司(以下简称数字人公司)关于募集资金 2023 年度存放与使用情况专项报告(以下简称募集资金年度存放与使用情况专项报告) 执行了鉴证工作。 一、对报告使用者和使用目的的限定 本鉴证报告仅供数字人公司年度报告披露时使用,不得用作任何其他目的。我们同意 将本鉴证报告作为数字人公司年度报告的必备文件,随同其他文件一起报送并对外披露。 二、管理层的责任 数字人公司管理层的责任是提供真实、合法、完整的相关资料,按照《北京证券交易 所股票上市规则(试行)》及相关格式指引的规定编制《关于募集资金年度存放与使用情 况的专项报告》,并保证其内容真实、准确、完整,不存在虚假记载、误导性陈 ...

山东数字人科技股份有限公司 内部控制鉴证报告 9/F Block A Fir Hila Mansi No 8 Chaovang men Reida Donachena District. Bei -86(010)6554 7190 索引 内部控制鉴证报告 1-2 3-10 关于内部会计控制制度有关事项的说明 . 信永中和会计师事务所 | 北京市东城区朝阳门北大街 8号富华大厦A座9层 +86(010)6554 2288 内部控制鉴证报告 XYZH/2024JNAA2B0100 山东数字人科技股份有限公司 山东数字人科技股份有限公司全体股东: 我们接受委托,对后附的山东数字人科技股份有限公司(以下简称数字人公司)管理层 按照《企业内部控制基本规范》及相关规定对 2023年 12 月 31 日与财务报表相关的内部 控制的自我评价报告执行了鉴证工作。 数字人公司管理层的责任是按照《企业内部控制基本规范》及相关规定建立健全内部 控制并保持其有效性,以及保证自我评估报告真实、准确、完整地反映与财务报表相关的 内部控制。我们的责任是对数字人公司与财务报表相关的内部控制有效性发表鉴证意见。 我们按照《中国注册会计师其他鉴证 ...

证券代码：835670 证券简称：数字人 公告编号：2024-032 公司拟利用最高额度不超过人民币 6,000 万元（含 6,000 万元）暂时闲置自 有资金购买中低风险理财产品，在前述额度内，资金可以滚动投资，即在投资期 限内的任何时点持有未到期投资产品总额不超过人民币 6,000 万元（含 6,000 万元） （三） 委托理财方式 山东数字人科技股份有限公司 关于使用闲置自有资金购买理财产品的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 委托理财概述 （一） 委托理财目的 为提高公司短期闲置自有资金的资金使用效率和收益，实现股东利益最大 化，在确保不影响公司日常生产经营活动所需资金及保障资金流动性和安全性的 前提下，公司拟在 2024 年利用自有闲置资金购买中低风险理财产品，以获取额 外的资金收益。 （二） 委托理财金额和资金来源 公司使用闲置自有资金购买理财产品是在确保公司日常运营所需流动资金 和资金安全的前提下实施的，不会影响公司业务的正常发展。通过适度的理财产 品投资，可以提高 ...

证券代码：835670 证券简称：数字人 公告编号：2024-030 山东数字人科技股份有限公司 对外投资的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、对外投资概述 （一）基本情况 山东数字人科技股份有限公司（以下简称"公司"）基于公司战略发展和业 务经营需要，进一步优化公司业务布局，拟设立全资子公司山东易盛进出口有限 公司，注册资本为 300 万元人民币，主营业务为货物及技术进出口（全资子公司 的名称、注册地址、经营范围等相关信息以当地市场监督管理部门最终核定为 准）。 （二）是否构成重大资产重组 本次交易不构成重大资产重组。 公司本次对外投资系新设全资子公司，不构成重大资产重组。 （三）是否构成关联交易 本次交易不构成关联交易。 （四）决策与审议程序 公司于 2024 年 4 月 16 日召开第三届董事会第十八次会议审议通过了《关于 投资设立全资子公司》的议案，同意 9 票，反对 0 票，弃权 0 票，本议案不涉及 关联交易，无需回避表决。根据《公司章程》及《对外投资管理制度》，本次对 ...